bioRxivImmunology
Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4+ T cell response
A. Chudnovskiy, T. B. Castro, S. Nakandakari-Higa, A. Cui, C.-H. Lin, M. Sade-Feldman, B. K. Phillips, J. Pae, L. Mesin, J. Bortolatto, L. D. Schweitzer, G. Pasqual, L.-F. Lu, N. Hacohen, G. D. Victora
Abstract
Dendritic cells (DCs) are uniquely capable of transporting tumoral antigens to tumor-draining lymph nodes (tdLNs), and also interact with effector T cells within the tumor microenvironment (TME) itself, mediating both natural antitumor immunity and the response to checkpoint blockade immunotherapy. Using LIPSTIC (Labeling Immune Partnerships by SorTagging Intercellular Contacts)-based single-cell transcriptomics, we identify individual DCs capable of presenting antigen to CD4+ T cells in the tdLN as well as inside the tumor microenvironment (TME). Our findings reveal that DCs with similar hyperactivated transcriptional phenotypes interact with helper T cells both within tumors and in the tdLN, and that checkpoint blockade drugs enhance these interactions. These findings show that a relatively small fraction of DCs is responsible for most of the antigen presentation within the tdLN and TME to both CD4+ and CD8+ tumor-specific T cells and that classical checkpoint blockade enhances CD40-driven DC activation at both sites.
- organism: mouse
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: cell-cell communication
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dendritic cell PD-L2 restrains intratumoral CD8+ T cell immunity
Jinwoo Nah, Amanda Sun, … Chrysothemis C. Brown·bioRxiv·Sep 16, 2026
- Tumor-specific draining lymph node CD8 T cells orchestrate an anti-tumor response to neoadjuvant PD-1 immune checkpoint blockade
Rachel Honigsberg, Tatiana Cruz, … Jonathan Villena‐Vargas·bioRxiv·Apr 27, 2025
- CD4+ follicular helper-like T cells are key players in anti-tumor immunity
D. Singh, A. P. Ganesan, … P. Vijayanand·bioRxiv·Jan 8, 2020
- OX40 agonism enhances efficacy of PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
G. Beyrend, T. C. van der Sluis, … R. Arens·bioRxiv·Dec 24, 2021
- Successful dendritic cell vaccines require lasting in-situ TNF α secretion to license antitumor CD8 + T cell cytotoxicity
Nadine Santana-Magal, Aseel Khateeb, … Yaron Carmi·bioRxiv·Apr 8, 2026
- Contextual control of CD8+ T cell priming by dendritic cell subsets in tumor and inflammatory microenvironments
Victoria P. Schuster, Naomi Berkowitz, … Megan K. Ruhland·Cell ReportsPeer-reviewed·Sep 29, 2026